A

AbbVie

Global biopharmaceutical company developing medicines

Data Engineer - AI Enablement

Full-TimeUpdated on 10/23/2026
$84.5k - $162k/yr+ Short-term incentive program
Senior
Bachelor's, Master's
North Chicago, IL, USA
Hybrid
Data & AnalyticsData Engineering

About the job

Requirements
  • A bachelor's degree with 5 years of experience, or a master's degree with 4 years of experience, in information technology, data engineering, data management, analytics, life sciences, or a related field.
  • Hands-on experience designing, developing, and operating production data pipelines and curated data products using SQL, Python, ETL/ELT patterns, and workflow orchestration tools such as Airflow.
  • Working knowledge of modern data platforms, data integration, data warehousing or lakehouse patterns, distributed SQL or big data environments, cloud infrastructure, and analytics enablement.
  • Experience preparing data for downstream analytics, machine learning, knowledge graph, or retrieval use cases, including cleaning, standardization, enrichment, structuring, metadata organization, and support for embedding or vector-search workflows.
  • Experience applying data quality, metadata management, governance, lineage, documentation, and data modeling practices to support trusted, reusable data products.
  • Experience collaborating with cross-functional business, scientific, technical, platform, vendor, contractor, or managed-services teams to translate requirements and deliver fit-for-purpose data assets.
  • Ability to operate with a high degree of autonomy, manage priorities across concurrent workstreams, modify approach when needed, escalate open issues, and keep stakeholders informed through clear written and verbal communication.
  • Demonstrated ability to learn, understand, and apply new data engineering, platform, and AI-enablement technologies, and to serve as a technical resource for others.
  • Experience providing technical input, clarifying requirements, and reviewing outputs from contracted, vendor, or managed-services engineers without direct reporting authority.
  • Strong communication, planning, and organizational skills, with the ability to explain technical concepts and keep stakeholders informed.
  • A data product engineering mindset, with the ability to shape reusable, well-structured data assets that are practical, scalable, and fit for analytics and AI-enabled use.
  • A data curation and stewardship mindset, with attention to quality, metadata, lineage, governance, standards, documentation, and appropriate use.
  • Technical fluency across data platforms, pipelines, integration patterns, orchestration, cloud environments, and data delivery practices sufficient to work effectively with engineering and platform teams.
  • Operational discipline across monitoring, troubleshooting, prioritization, issue resolution, automation, reusable patterns, and continuous improvement.
  • Technical coordination and influence, with the ability to clarify priorities, guide work, review outputs, resolve ambiguity, and coordinate across internal and external contributors.
  • Stakeholder communication, with the ability to frame tradeoffs, risks, dependencies, and progress clearly for technical, scientific, and business audiences.
Responsibilities
  • Design, build, and operate curated, reusable data products that make high-value R&D data easier to find, connect, understand, and use.
  • Collect, integrate, normalize, model, and transform data from databases, applications, APIs, licensed external sources, and other systems into ARCH and related data environments.
  • Establish reliable, scalable data foundations supporting analytics, reporting, knowledge graph capabilities, machine learning, and AI-enabled use cases.
  • Ensure data assets are structured, documented, accessible, governed, traceable, and fit for downstream consumption.
  • Prepare data and documents for AI and knowledge discovery use cases by cleaning, standardizing, enriching, labeling, organizing metadata, supporting chunking and embedding workflows, and producing vector database-ready assets.
  • Enable publication of curated data to the ARCH knowledge graph.
  • Apply data quality and governance practices, including accuracy and completeness checks, metadata, lineage, access controls, privacy, license terms, assumptions, quality rules, and appropriate-use guidance.
  • Collaborate with data scientists, machine learning engineers, software engineers, platform teams, architects, data owners, and R&D stakeholders to translate scientific and business requirements into usable AI-ready data products.
  • Provide technical guidance to contracted engineers, clarify work, review outputs, help remove barriers, and support delivery against agreed quality and acceptance standards.
  • Monitor pipeline performance, data freshness, cost, failures, and delivery issues; troubleshoot and resolve problems before they affect data consumers.
  • Contribute to reusable engineering patterns, automation, process improvements, and consistent ways of working across data product workflows.
  • Follow applicable Corporate and Divisional policies, including GxP compliance, data security, software development lifecycle practices, data governance standards, and relevant regulatory or contractual requirements.
Desired Qualifications
  • Pharmaceutical or healthcare industry experience.
  • Experience supporting research, discovery, translational, clinical, scientific, or other life sciences data environments.
  • Familiarity with graph databases, knowledge graphs, ontology-based data structures, semantic data, metadata-driven data products, or linked-data concepts.
  • Experience working with AWS-based, cloud-based, lakehouse, or modern data platform technologies such as Databricks, Spark, Snowflake, Neo4j, or similar tools.
  • Experience working with regulated data environments, including data governance, documentation, security, privacy, license terms, or compliance expectations.
  • Exposure to analytics, machine learning, retrieval-augmented generation (RAG), embeddings, vector databases, AI-search patterns, or AI-ready data product delivery.
  • Familiarity with Agile practices or planning tools such as Jira, including backlog refinement, sprint planning, prioritization, acceptance criteria, and delivery tracking.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.